Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression

• Published in: ESMO open 2022-12, Vol.7 (6), p.100636-100636, Article 100636
• Main Authors: Giannoudis, A., Varešlija, D., Sharma, V., Zakaria, R., Platt-Higgins, A., Rudland, P.S., Jenkinson, M.D., Young, L.S., Palmieri, C.
• Format: Article
• Language: English
• Subjects: ARG2; Arginase - genetics; Arginase - metabolism; B7 Antigens - metabolism; B7-H1 Antigen - genetics; B7-H1 Antigen - metabolism; brain metastasis; Brain Neoplasms - secondary; breast cancer; Breast Neoplasms - immunology; Breast Neoplasms - pathology; CTLA-4 Antigen - genetics; Female; Humans; immuno-oncology; Original Research; T-Lymphocytes; TIL; Tumor Microenvironment
• ISSN: 2059-7029; 2059-7029
• DOI: 10.1016/j.esmoop.2022.100636

Immune checkpoint inhibition is an established treatment in programmed death-ligand 1 (PD-L1)-positive metastatic triple-negative (TN) breast cancer (BC). However, the immune landscape of breast cancer brain metastasis (BCBM) remains poorly defined. The tumour-infiltrating lymphocytes (TILs) and the messenger RNA (mRNA) levels of 770 immune-related genes (NanoString™, nCounter™ Immuno-oncology IO360) were assessed in primary BCs and BCBMs. The prognostic role of ARG2 transcripts and protein expression in primary BCs and its association with outcome was determined. There was a significant reduction of TILs in the BCBMs in comparison to primary BCs. 11.5% of BCs presented a high immune infiltrate (hot), 46.2% were altered (immunosuppressed/excluded) and 34.6% were cold (no/low immune infiltrate). 3.8% of BCBMs were hot, 23.1% altered and 73.1% cold. One hundred and twelve immune-related genes including PD-L1 and CTLA4 were decreased in BCBM compared to the primary BCs (false discovery rate 1.5). These genes are involved in matrix remodelling and metastasis, cytokine–chemokine signalling, lymphoid compartment, antigen presentation and immune cell adhesion and migration. Immuno-modulators such as PD-L1 (CD274), CTLA4, TIGIT and CD276 (B7H3) were decreased in BCBMs. However, PD-L1 and CTLA4 expression was significantly higher in TN BCBMs (P = 0.01), with CTLA4 expression also high in human epidermal growth factor receptor 2-positive (P < 0.01) compared to estrogen receptor-positive BCBMs. ARG2 was one of four genes up-regulated in BCBMs. High ARG2 mRNA expression in primary BCs was associated with worse distant metastasis-free survival (P = 0.038), while ARG2 protein expression was associated with worse breast–brain metastasis-free (P = 0.027) and overall survival (P = 0.019). High transcript levels of ARG2 correlated to low levels of cytotoxic and T cells in both BC and BCBM (P < 0.01). This study highlights the immunological differences between primary BCs and BCBMs and the potential importance of ARG2 expression in T-cell depletion and clinical outcome. •BCBMs are immunologically more inactive than primary BCs.•BCBMs have less TILs and reduced PD-L1 and CTLA4 transcript levels than primary BCs.•Transcripts of PD-L1 and CTLA4 are higher in TN BCBMs as compared to other BCBM subtypes.•ARG2 expression could be indicative of a depleted T-cell response in BCBM.•ARG2 could be a potential marker of BC distant metastasis and a therapeutic ta